JFG
ZVRA icon

Jefferies Financial Group’s Zevra Therapeutics ZVRA Stock Holding History

Jefferies Financial Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,000
Closed -$1.08M – 2280
2025
Q4 		$1.08M Buy
+120,000
New +$1.13M 0.01% 1039

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jefferies Financial Group's ZVRA Position: Q1 2026 in Review

Jefferies Financial Group sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 120,000 shares — an estimated $1.08M sold.

Jefferies Financial Group first reported a position in ZVRA in Q4 2025 and held it in 1 quarter. The position peaked at $1.08M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Jefferies Financial Group reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 120,000 Zevra Therapeutics shares in Q1 2026, an estimated $1.08M.
  • Jefferies Financial Group first reported a position in Zevra Therapeutics in Q4 2025 and held it in 1 quarter.
  • Jefferies Financial Group's Zevra Therapeutics position peaked at $1.08M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.